查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
HIV治療藥的全球市場:市場規模 - 各藥物類別，各投藥法，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1174975

HIV治療藥的全球市場:市場規模 - 各藥物類別，各投藥法，各流通管道，各地區展望，競爭策略，各市場區隔預測(～2032年)

HIV Drugs Market Size- By Drug Class, By Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 232 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球HIV治療藥的市場規模，預計至2032年達到4,974萬美元，預計以4.05％的年複合成長率成長。

HIV的感染率和診斷數增加，是牽引全球市場的成長的重要要素之一。以提高原因、症狀、治療方法相關國民的知識為目的的政府活動增加，也帶給市場影響。

本報告提供全球HIV治療藥市場相關調查，市場動態，市場變數與展望，各藥物類別、投藥法、流通管道、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球HIV治療藥市場上COVID-19的影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球HIV治療藥市場:各藥物類別(2019年～2032年(100萬美元))

  • 趨化素受體抑制劑
  • 進入抑制劑 - CCR5共受體拮抗劑
  • 融合抑制劑
  • 整合抑制劑，HIV整合酶鏈轉移抑制劑
  • 多級組合產品，蛋白酶抑制劑
  • 非核苷系逆轉錄酶抑制劑(NNRT)
  • 核苷系逆轉錄酶抑制劑(NRT)

第7章 全球HIV治療藥市場:各投藥法(2019年～2032年(100萬美元))

  • 口服
  • 非口服

第8章 全球HIV治療藥市場:各流通管道(2019年～2032年(100萬美元))

  • 醫院藥局
  • 線上藥局
  • 零售藥局
  • 其他

第9章 全球HIV治療藥市場:各地區(2019年～2032年(100萬美元))

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第10章 企業簡介

  • Abbvie Inc.
    • 企業概要
    • 財務展望
    • 產品概要
    • 最近的開發
  • Aelix Therapeutics
  • AIM ImmunoTech
  • BioNTech
  • Biosantech
  • Boehringer Ingelheim International GmbH
  • Bristrol-Myers Squibb Company
  • CytoDyn
  • Dewpoint Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline
  • ImmunityBio
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • Merck
  • Mylan
  • Roche
  • Shionogi
  • Starpharma
  • TaiMed Biologics
  • Theratechnologies
  • ViiV Heathcare
簡介目錄
Product Code: PHAR2213

Global HIV Drugs Market Overview:

According to SPER Market Research, the Global HIV Drugs Market is estimated to reach USD 49.74 million by 2032 with a CAGR of 4.05%.

The chronic and potentially fatal human immunodeficiency virus (HIV) can be spread to humans to another through sexual contact and blood-to-blood contact. It is a virus that targets CD-4 cells, which are immunological cells, rendering the body more vulnerable to infections and other disorders. The demand for HIV medications has benefited from the increasing incidence of HIV illness throughout time. HIV medications assist in inhibiting HIV replication, hence lowering the risk of transmission. The increase in HIV prevalence and its diagnosis is one of the key reasons driving the growth of the worldwide market for HIV medications. In addition, a growth in the number of government activities aimed at raising public knowledge of causes, symptoms, and treatments has an impact on the market. The availability of generic medications, which are as effective and chemically equivalent to branded medications, is another factor influencing the demand for HIV medications.

Impact of COVID-19 on the Global HIV Drugs Market

Global healthcare goods import, and export have been hampered by the COVID-19 epidemic. Because of the disruption and volatility in the medicine supply, the pandemic has had a negative effect on the growth of this industry. Additionally, the demand for antiretroviral and antibiotic drugs has decreased internationally due to the decline in the number of new patient prescriptions in the United States, Europe, and other COVID-affected areas and nations. The majority of businesses have seen a negative effect of the epidemic on the sales of HIV/AIDS medications.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Drug Class, By Administration, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Abbvie Inc., Aelix Therapeutics, AIM ImmunoTech, BioNTech, Biosantech, Boehringer Ingelheim International GmbH, Bristrol-Myers Squibb Company, CytoDyn, Dewpoint Therapeutics, Gilead Sciences, GlaxoSmithKline, ImmunityBio, Janssen Pharmaceuticals, Japan Tobacco, Merck, Mylan, Roche, Shionogi, Starpharma, TaiMed Biologics, Theratechnologies, ViiV Healthcare.

Global HIV Drugs Market Segmentation:

  • By Drug Class: Based on the Drug Class, Global HIV Drugs Market is segmented as; Chemokine Receptor Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, Fusion Inhibitors, Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors, Multi-Class Combination Products, Protease Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Nucleoside Reverse Transcriptase Inhibitors (NRT's).
  • By Administration: Based on the Administration, Global HIV Drugs Market is segmented as; Oral, Parenteral.
  • By Distribution Channel: Based on the Distribution Channel, Global HIV Drugs Market is segmented as; Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others.
  • By Region: The worldwide market may be divided into three regions based on geography: North America, Europe, and the rest of the world. It is expected that North America would predominate. The rising incidence of HIV infection among Americans is to blame for this region's dominance. The demand for HIV medications is greatly increased by a large patient base. The population's awareness is another element influencing the progress of the region. Additionally, the existence of major companies that provide cutting-edge HIV medications for the treatment of HIV infection will further accelerate market expansion. Rapid increase in the number of HIV infections and the abundance of HIV medicine manufacturers in this area, Europe is anticipated to be the second-largest market throughout the projection period.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global HIV Drugs Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global HIV Drugs Market, By Drug Class, 2019-2032 (USD Million)

  • 6.1. Chemokine Receptor Inhibitors
  • 6.2. Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • 6.3. Fusion Inhibitors
  • 6.4. Integrate Inhibitors, HIV Integrase Strand Transfer Inhibitors
  • 6.5. Multi-Class Combination Products, Protease Inhibitors
  • 6.6. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
  • 6.7. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

7. Global HIV Drugs Market, By Administration, 2019-2032 (USD Million)

  • 7.1. Oral
  • 7.2. Parenteral

8. Global HIV Drugs Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1. Hospital Pharmacies
  • 8.2. Online Pharmacies
  • 8.3. Others
  • 8.4. Retail Pharmacies

9. Global HIV Drugs Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Abbvie Inc.
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Aelix Therapeutics
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 AIM ImmunoTech
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 BioNTech
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Biosantech
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 Boehringer Ingelheim International GmbH
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Bristrol-Myers Squibb Company
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 CytoDyn
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 Dewpoint Therapeutics
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Gilead Sciences
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments
  • 10.11 GlaxoSmithKline
    • 10.11.1 Company details
    • 10.11.2 Financial outlook
    • 10.11.3 Product summary
    • 10.11.4 Recent developments
  • 10.12 ImmunityBio
    • 10.12.1 Company details
    • 10.12.2 Financial outlook
    • 10.12.3 Product summary
    • 10.12.4 Recent developments
  • 10.13 Janssen Pharmaceuticals
    • 10.13.1 Company details
    • 10.13.2 Financial outlook
    • 10.13.3 Product summary
    • 10.13.4 Recent developments
  • 10.14 Japan Tobacco
    • 10.14.1 Company details
    • 10.14.2 Financial outlook
    • 10.14.3 Product summary
    • 10.14.4 Recent developments
  • 10.15 Merck
    • 10.15.1 Company details
    • 10.15.2 Financial outlook
    • 10.15.3 Product summary
    • 10.15.4 Recent developments
  • 10.16 Mylan
    • 10.16.1 Company details
    • 10.16.2 Financial outlook
    • 10.16.3 Product summary
    • 10.16.4 Recent developments
  • 10.17 Roche
    • 10.17.1 Company details
    • 10.17.2 Financial outlook
    • 10.17.3 Product summary
    • 10.17.4 Recent developments
  • 10.18 Shionogi
    • 10.18.1 Company details
    • 10.18.2 Financial outlook
    • 10.18.3 Product summary
    • 10.18.4 Recent developments
  • 10.19 Starpharma
    • 10.19.1 Company details
    • 10.19.2 Financial outlook
    • 10.19.3 Product summary
    • 10.19.4 Recent developments
  • 10.20 TaiMed Biologics
    • 10.20.1 Company details
    • 10.20.2 Financial outlook
    • 10.20.3 Product summary
    • 10.20.4 Recent developments
  • 10.21 Theratechnologies
    • 10.21.1 Company details
    • 10.21.2 Financial outlook
    • 10.21.3 Product summary
    • 10.21.4 Recent developments
  • 10.22 ViiV Heathcare
    • 10.22.1 Company details
    • 10.22.2 Financial outlook
    • 10.22.3 Product summary
    • 10.22.4 Recent developments